Assobiotec - English version

30 July 2024

AGC Biologics’ Seattle Site Achieves Successful Multi-Product Inspection by U.S. Food and Drug Administration for Biologics License Applications

CDMO site shares promising outcomes after in Q1 2024 FDA inspections and is now producing two new products for commercial usage in the U.S.

10 May 2024

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Chiesi Farmaceutici S.p.A., an international, research-focused biopharmaceutical group, and Gossamer Bio, a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.

25 March 2024

Agreement between Bioindustry Park and Federated Innovation @Mind to accelerate the creation of a virtual district in life science

Working together to develop an innovative and competitive healthcare ecosystem, by focusing on digital and healthcare innovation trends, and strengthening the research and internationalisation of the production sector. This is the aim of the collaboration agreement signed by Federated Innovation @MIND and Bioindustry Park Silvano Fumero, reference points for companies in Lombardy and Piedmont operating in the public and private health and Life Sciences sectors.

08 January 2024

Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide

290 patients participate at study centers in Europe, Asia and Latin America. Results from the study are expected in March 2024.

21 December 2023

Axxam and Lundbeck's Partnership for Lead Identification

The signature of this first partnership agreement between Axxam and Lundbeck, for the identification and qualification of small molecules relevant to CNS targets, comes after more than five years of successful collaboration in assay development and High-Throughput Screening.

16 November 2023

Momentum Biotechnologies and Axxam S.p.A. Announce Collaboration to Provide Unique Drug Discovery Solutions

Through the partnership Axxam’s highly curated chemical diversity library, comprised of 325,000 compounds, will be available for high-throughput screening using Momentum’s mass spectrometry-based func􀀛onal and binding assay platforms.

News

AGC Biologics’ Seattle Site Achieves Successful Multi-Product Inspection by U.S. Food and Drug Administration for Biologics License Applications

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Agreement between Bioindustry Park and Federated Innovation @Mind to accelerate the creation of a virtual district in life science

Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide

Axxam and Lundbeck's Partnership for Lead Identification

Momentum Biotechnologies and Axxam S.p.A. Announce Collaboration to Provide Unique Drug Discovery Solutions

Partner

Where to find us